The mutations in the quinolone resistance-determining region of the gyrA and gyrB genes from 27 clinical isolates of Escherichia coli with a range of MICs of ciprofloxacin from 0.007 to 128 ,ug/ml and of nalidixic acid from 2 to >2,000 ,ug/ml were determined by DNA sequencing. All 15 isolates with ciprofloxacin MICs of .1 ,ug/ml showed a change in Ser-83 to Leu of GyrA protein, whereas in clinical isolates with a MIC of .8 ,ug/ml (11 strains), a double change in Ser-83 and Asp-87 was found. All isolates with a MIC of nalidixic acid of .128 ,ug/ml showed a mutation at amino acid codon Ser-83. Only 1 of the 27 clinical isolates of E. coli analyzed showed a change in Lys-447 of the B subunit of DNA gyrase. A change in Ser-83 is sufficient to generate a high level of resistance to nalidixic acid, whereas a second mutation at Asp-87 in the A subunit of DNA gyrase may play a complementary role in developing the strain's high levels of ciprofloxacin resistance.
New fluoroquinolones are broad-spectrum antibacterial agents which inhibit DNA gyrase activity (26) . DNA gyrase contains two subunits of GyrA and two subunits of GyrB (13, 19) . Gyrase A mediates DNA strand breakage and reunion with the Tyr residue at position 122 forming a transient phosphotyrosine linkage with a broken DNA strand. The mechanisms of quinolone resistance essentially fall into two classes: (i) mutations in gyrA (1, 2, 5, 6, 8, 17, 28, 30) or gyrB genes (27, 29) or (ii) reduced levels of quinolone accumulation in the cells (3, 4, (9) (10) (11) (12) . The mutations in the gyrA gene involved in the resistance are clustered in a region between nucleotides 199 (Ala-67) and 318 (Gln-106), which contains nucleotide 247 (Ser-83), the most frequently changed in spontaneus gyrA mutations. In the gyrB gene, two quinolone resistance-determining sites (amino acids 426 and 447) have been found (27, 29) . The mutation at amino acid codon Asp-426 confers resistance to nalidixic acid and the new fluoroquinolones, whereas the change of Lys-447 results in resistance to nalidixic acid and increased susceptibility to the fluoroquinolones (29 testing was performed by using an agar dilution method and in accordance with the guidelines established by the National Committee for Clinical Laboratory Standards (16) . Approximately 104 CFU of each isolate was inoculated onto freshly prepared media containing serial dilutions of ciprofloxacin (Bayer, Leverkusen, Germany) or nalidixic acid (Prodesfarma, Barcelona, Spain) with a multipoint replicator. To identify gyrA and gyrB mutations in resistant isolates, PCR and direct DNA sequencing were used. A DNA fragment of 648 bp, from nucleotides 24 to 671 of the gyrA gene, was obtained according to the procedure described by Oram and Fisher (17) , with slight modifications. To amplify the fragment of gyrB, from nucleotides 995 to 1442, two 20-mer oligonucleotide primers, 5' CTC CTC CCA GAC CAA AGA CA 3' and 5' TCA CGA CCG ATA CCA CAG CC 3', were used. The PCR program used was the same as that for gyrA gene amplification. The primers used were from MedProbe (Oslo, Norway). Reactions were performed in a DNA Thermal Cycler 480 (Perkin-Elmer Cetus, Emeryville, Calif.). DNA analysis by agarose gel electrophoresis revealed amplification of the expected 648-bp fragment for the gyrA gene and a 447-bp fragment for the gyrB gene in each case. Both fragments contained the quinolone resistance-determining region of gyrA and gyrB genes, respectively. Primers and free nucleotides from PCRs were removed with Stratagene's PrimeErase Quik, according to the manufacturer's instructions. After that, the sample was directly processed for DNA sequencing with Taq DyeDeoxiTerminator Cycle Sequencing Kit and analyzed in an automatic DNA Sequencer (Applied Biosystems 373A).
The mutations in the gyrA gene leading to amino acid changes are shown in Table 1 (20) (21) (22) . Willmott and Maxwell (25) correlated the mutation of Ser-83 to Trp with the reduction of drug binding to the protein-DNA complex to 60-fold less than that of wild-type gyrase A. Therefore, further investigation is necessary to show whether both mutations found in this study are associated with a higher reduction of drug binding. The explanation of the interaction of quinolones with DNA gyrase and DNA remains controversial since several models have been described previously (14, 18, 21) . We have applied molecular modeling (molecular mechanics calculations with the Discover package from Biosym Technologies Inc.) to compare the distance between the substituent at C-7 and the substituent at N-1 in ciprofloxacin with the distance between Ser-83 and Asp-87 of GyrA protein. These calculations were performed for different protein conformations ranging from an a-helix to a completely extended form. We have found that the distance between both substituents (ca. 9 A [0.9 nm]) fits well with the range of calculated distances between the functional groups of Ser-83 and Asp-87 side chains (3.5 and 14 A [0.35 and 1.4 nm] for oa-helix and extended forms, respectively).
We have only examined the quinolone resistance-determining regions of gyrA and gyrB genes; therefore, it is possible that alterations in permeability together with a change in Ser-83 and Asp-87 of GyrA may modulate the ultimate MIC level for these strains. However, in the light of these results the hypothesis of the gyrA gene presenting two major points of binding to quinolones is of interest. A change in Ser-83 generates a high level of resistance to nalidixic acid but a low level of resistance to ciprofloxacin, and the mutation in Asp-87 may play a complementary role in developing the strain's high levels of ciprofloxacin resistance.
